Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis

Basit Öğe Kaydı
dc.contributor.authorÜstündag-Okur N.
dc.contributor.authorGökçe E.H.
dc.contributor.authorBozbiyik D.I.
dc.contributor.authorEgrilmez S.
dc.contributor.authorÖzer Ö.
dc.contributor.authorErtan G.
dc.date.accessioned2019-10-26T21:27:29Z
dc.date.available2019-10-26T21:27:29Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractThe objective of this study was to explore the potential of the nanostructured lipid carriers (NLCs) modified with chitosan oligosaccharide lactate (COL) for topical ocular application. Ofloxacin (OFX) loaded NLCs were prepared by microemulsion or high shear homogenization methods. For combination of NLCs Compritol HD5 ATO was used as solid lipid, oleic acid as liquid lipid, Tween 80 as surfactant, ethanol as co-surfactant. The optimum NLCs was modified with 0.75% COL. The properties of NLCs in the absence or presence of OFX (0.3%) were characterized as zeta potential, particle size, viscosity and pH, TEM, drug loading, encapsulation efficiency and anti-microbial properties. Ex-vivo penetration/permeation studies were performed with rabbit cornea in Franz-diffusion cells. The penetration rate of OFX from NM-COL4OFX and NH-COL4OFX were significantly higher than commercial solution. Based on the selected formulations, in vivo tests were carried out by eye-drop instillation of NLCs in rabbit. The addition of COL improved the preocular residence time, controlled the drug release and enhanced the corneal bioavailability. In conclusion, OFX COL modified NLCs prepared by high shear homogenization method could be offered as a promising strategy for ocular drug delivery. © 2014 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorship10/ECZ/014en_US
dc.description.sponsorshipThis study was supported by University of Ege, Scientific Research Projects No: 10/ECZ/014. The authors would like to thank to Ege University, Faculty of Pharmacy, Department of Microbiology and Ege University, Faculty of Pharmacy, Pharmaceutical Sciences Research Center (FABAL) for U-HPLC studies. --en_US
dc.identifier.doi10.1016/j.ejps.2014.07.013en_US
dc.identifier.endpage215en_US
dc.identifier.issn0928-0987
dc.identifier.pmid25111119en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage204en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejps.2014.07.013
dc.identifier.urihttps://hdl.handle.net/11454/17415
dc.identifier.volume63en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Pharmaceutical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBacterial keratitisen_US
dc.subjectNanostructured lipid carriersen_US
dc.subjectOcular deliveryen_US
dc.subjectOfloxacinen_US
dc.subjectTopical applicationen_US
dc.titlePreparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu